Semaglutide produces meaningful, sustained weight loss for two or more years in large randomized clinical trials. The STEP 1, STEP 5, and SELECT trials — spanning 68 weeks to four years — show consistent results: weight loss continues for more than a year, plateaus, then holds. Subject to medical approval by a licensed provider.
If you've started a GLP-1 program and wondered whether results hold up, the answer from the clinical data is yes — with a clear caveat about what happens when you stop. Here's what the trials actually found.
The STEP 1 Trial: 68 Weeks of Data
The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with overweight or obesity (without type 2 diabetes). Participants received semaglutide 2.4 mg weekly plus lifestyle counseling or placebo for 68 weeks.
Key findings:
- Mean weight loss: -14.9% from baseline in the semaglutide group vs. -2.4% with placebo
- 86% of semaglutide participants lost ≥5% of body weight; 50% lost ≥15%
- Weight loss continued through week 60, then plateaued — not reversed
- Improvements in waist circumference, blood pressure, HbA1c, and lipids alongside weight
Weight loss with semaglutide stems from reduced energy intake driven by central appetite suppression, not stimulants or diuretics. This distinction matters for understanding the long-term picture.
Source: Wilding et al., NEJM 2021
STEP 5: Two-Year Results
STEP 5 extended the semaglutide 2.4 mg trial to 104 weeks (two years) in a similar population. The question was whether the plateau from STEP 1 held, or whether weight crept back while still on medication.
Answer: the plateau held.
- At week 104, participants on semaglutide maintained a mean weight loss of approximately -15.2% from baseline
- 67.8% maintained ≥5% weight loss at two years
- 44.2% maintained ≥10% weight loss
- Cardiometabolic improvements (blood pressure, lipids, blood sugar) persisted
This addressed the "what happens after the plateau" question directly. Semaglutide appears to reset a new defended weight set-point, which is maintained as long as therapy continues.
Source: Garvey et al., Nature Medicine 2022 (STEP 5)
The SELECT Trial: Four Years of Evidence
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial ran for up to four years (208 weeks) in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes. The primary endpoint was cardiovascular events — but the weight data adds something important.
Weight outcomes at four years:
- Mean weight loss at week 208: -10.2% in the semaglutide group vs. -1.5% with placebo
- Weight-loss trajectory continued through week 65, then was sustained through week 208 — no rebound while on treatment
- Waist circumference reduced by 7.7 cm (vs. 1.3 cm for placebo)
- Semaglutide group had fewer serious adverse events across all BMI categories
The SELECT population wasn't enrolled specifically for weight loss (they had existing cardiovascular disease), which explains the slightly smaller percentage compared to STEP trials. Still, at four years on medication, the weight was maintained.
Source: Bhatt et al., Nature Medicine 2024 (SELECT weight analysis)
Trial Comparison: What Each Study Found
| Trial | Duration | Population | Mean Weight Loss | Key Outcome |
|---|---|---|---|---|
| STEP 1 | 68 weeks (~16 months) | Obesity/overweight, no T2D | -14.9% | Efficacy established; weight nadir ~week 60 |
| STEP 5 | 104 weeks (2 years) | Obesity/overweight, no T2D | -15.2% | Plateau holds; results durable at 2 years |
| SELECT | 208 weeks (4 years) | Overweight/obese with CVD | -10.2% | Sustained 4-year weight maintenance; CV benefit |
What Happens When You Stop Semaglutide
The STEP 1 withdrawal extension study (STEP 1 extension, published 2022) tracked participants for one year after stopping semaglutide. By week 120, participants who discontinued regained about two-thirds of lost weight. Mean weight returned to roughly -5.6% from original baseline (vs. -17.4% at the end of treatment in continuers).
This isn't unique to semaglutide — it reflects the biological reality of obesity as a chronic, relapsing condition. The body fights to return to its prior set-point when the pharmacological signal is removed. This is why clinical guidance increasingly frames GLP-1 therapy as long-term, not a short course.
If you're considering what happens after stopping, see our full guide: Stopping Semaglutide: What to Expect.
Long-Term Safety: What the Evidence Shows
Across STEP and SELECT trials, the semaglutide safety profile was consistent:
- Most common side effects: nausea, diarrhea, vomiting — typically transient and mild-to-moderate in the early titration phase
- Discontinuation due to GI events: ~4.5% in STEP 1 (vs. 0.8% placebo)
- Serious adverse events: LOWER in semaglutide groups across all BMI categories in SELECT
- Gallbladder events: slightly elevated incidence with semaglutide — consistent with rapid weight loss from any cause
- Pancreatitis: no significant increase compared to placebo
Four years of SELECT data represents the longest prospective randomized safety follow-up for semaglutide to date. The cardiovascular benefit — a 20% reduction in major adverse cardiovascular events — provides an additional safety-efficacy picture that extends beyond weight.
Who Responds Best to Semaglutide Long-Term
The trials show variation. A few patterns emerge from the data:
- Higher baseline BMI → greater percentage weight loss (in SELECT, lower BMI groups lost less proportionally)
- Women tended to lose more weight than men in SELECT (treatment difference -11.1% vs. -7.5%)
- Those without diabetes generally showed larger reductions than those with T2D (different receptor sensitivity and baseline insulin dynamics)
- Early responders (≥5% loss by week 16) were more likely to maintain meaningful loss long-term
If you're evaluating whether semaglutide is appropriate for your specific situation, an asynchronous provider review — like the evaluation process at TelosRX — can assess your history, labs, and goals before any prescription is issued.
For a comparison of compounded semaglutide vs. tirzepatide, see: Tirzepatide vs Semaglutide: GLP-1 Options Explained.
Compounded Semaglutide and What "Long-Term" Means for Access
The clinical trial data uses FDA-approved semaglutide (Wegovy). Compounded semaglutide is not FDA-approved and is prepared under federal compounding regulations. The pharmacological basis is the same active ingredient, but compounded formulations don't carry the clinical trial label.
What this means practically: compounded semaglutide is an option subject to provider evaluation and applicable regulations. The long-term weight outcomes described above come from trials of the approved formulation. Compounded access still requires medical approval by a licensed provider.
See our guide on compounded semaglutide via telehealth for access details.
Frequently Asked Questions
How long does semaglutide work for weight loss?
Clinical trial data shows sustained weight loss for up to four years while on treatment. The STEP 5 trial confirmed results hold at two years; the SELECT trial extended this to four. Weight loss typically plateaus around 60-65 weeks on the full dose, then holds without significant rebound while therapy continues. Individual results vary.
Does weight come back after stopping semaglutide?
Yes — the STEP 1 extension study found that participants regained approximately two-thirds of lost weight within one year of stopping. This reflects the biology of obesity as a chronic condition. Most clinical guidelines now recommend GLP-1 therapy as long-term maintenance, not a short course, consistent with how other chronic conditions are managed.
What did the STEP 5 trial show?
The STEP 5 trial showed that semaglutide 2.4 mg weekly produced and maintained an average weight loss of approximately 15% at two years. About 68% of participants maintained at least 5% weight loss and 44% maintained at least 10% weight loss at the two-year mark. Cardiometabolic improvements persisted throughout.
Is semaglutide safe for long-term use?
The SELECT cardiovascular outcomes trial ran for up to four years and showed that semaglutide was associated with fewer serious adverse events than placebo across all BMI categories. Nausea and GI side effects are the most common concerns, typically occurring early in treatment. Gallbladder events are slightly elevated with any significant weight loss intervention. Ongoing monitoring by a licensed provider is standard.
How much weight can you lose on semaglutide in 2 years?
The STEP 5 trial (two-year data) showed an average of approximately 15.2% body weight reduction from baseline. Individual responses vary based on starting BMI, adherence to lifestyle changes, and dose completion. One-third of participants in STEP 1 lost 20% or more of their body weight by week 68.
Does semaglutide affect cardiovascular health?
The SELECT trial enrolled participants specifically because of existing cardiovascular disease. Semaglutide produced a 20% relative risk reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared to placebo — alongside the sustained weight loss described above. This cardiovascular benefit is a separate finding from the weight data but comes from the same long-term trial.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.